Monday - November 3, 2025
Johnson & Johnson's INLEXZO Plus Cetrelimab Delivers Strong Pre-surgical Results in Patients With Muscle Invasive Bladder Cancer Scheduled for Radical Cystectomy
October 21, 2025
RARITAN, New Jersey, Oct. 21 -- Johnson and Johnson Innovative Medicine (formerly the Janssen Pharmaceutical Companies of Johnson and Johnson) issued the following news release on Oct. 20, 2025:

* * *

Johnson & Johnson's INLEXZO (gemcitabine intravesical system) plus cetrelimab delivers strong pre-surgical results in patients with muscle invasive bladder cancer scheduled for radical cystectomy

Phase 2b SunRISe-4 study shows 38% of patients treated . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products